SARS-CoV-2 Genomic Surveillance in North Louisiana

摘要 病毒基因组监测对于鉴定SARS-CoV-2变异体至关重要， 关注公共卫生的特征，如逃避体液免疫，增强的传染性， 和/或增加的致病潜力。这一竞争性修订提案代表了以下方面的合作： 两个路易斯安那州立大学健康什里夫波特（LSUHS）CoBRE（氧化还原生物学和心血管疾病中心[CRBCD]） 和应用免疫学和病理过程中心[CAIPP]），并利用现有的机构 包括新兴病毒威胁中心（CEVT）CLIA/CAP认证参考实验室在内的计划， 持续的COVID-19临床研究，社区大规模疫苗接种和检测服务，以及高效的 病毒基因组测序计划，在整个大流行期间为路易斯安那州北部和中部服务。 此外，LSUHS与路易斯安那州卫生部（LDH）积极合作开展这些工作， 将病毒基因组监测数据转化为有利的公共卫生结果的坚实基础， 作为保护脆弱社区和针对令人关切的变种采取有针对性的缓解措施。因此，这 竞争性修订补充将追求以下两个具体目标：目标1）建立快速SARS-CoV- 2病毒基因组测序和数据共享优先考虑再感染和疫苗感染 目标2）对中度至中度感染者进行SARS-CoV-2病毒基因组测序和数据共享。 有易感风险因素和/或心肺并发症的严重COVID-19患者。 总之，这项工作将大大加强路易斯安那州、得克萨斯州东部和 南阿肯色州有利于美国公共卫生和推进对这种毁灭性病毒的研究。

ABSTRACT Viral genomic surveillance is critical for identification of SARS-CoV-2 variants that exhibit biological characteristics of concern for public health, such as escape from humoral immunity, enhanced transmissibility, and/or increased pathogenic potential. This competitive revision proposal represents a collaboration between two LSU Health Shreveport (LSUHS) CoBRE’s (Center for Redox Biology and Cardiovascular Disease [CRBCD] and Center for Applied Immunology and Pathological Processes [CAIPP]) and leverages established institutional programs including the Center for Emerging Viral Threats’ (CEVT) CLIA/CAP certified reference laboratory, ongoing COVID-19 clinical research, community mass vaccination and testing services, and a highly productive viral genome sequencing program that have served North and Central Louisiana throughout the pandemic. Additionally, LSUHS is in active partner with the Louisiana Department of Health (LDH) for these efforts and has a strong foundation for translation of viral genomic surveillance data into favorable public health outcomes, such as protection of vulnerable communities and targeted mitigation steps against variants of concern. As such, this competitive revision supplement will pursue the following two specific aims: Aim 1) Establish rapid SARS-CoV- 2 viral genome sequencing and data sharing prioritized by re-infections and infections of vaccine recipients; and Aim 2) Perform SARS-CoV-2 viral genome sequencing and data sharing of moderate to severe COVID-19 patients with predisposing risk factors and/or cardiopulmonary complications. Together, this work will greatly enhance genomic surveillance of SARS-CoV-2 in Louisiana, East Texas, and Southern Arkansas to benefit US public health and advance research regarding this devastating virus.